1. Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome
- Author
-
Christine Gstrein, Giovanni Pedrazzini, Iveta Petrova-Slater, Jürg Grünenfelder, Elena Pasotti, Peiman Jamshidi, Paul Erne, Francesco Faletra, Roberto Corti, Thomas F. Lüscher, Oliver Gaemperli, Michel Zuber, Tiziano Moccetti, Patric Biaggi, Stefan Toggweiler, Daniel Sürder, and University of Zurich
- Subjects
COPD ,medicine.medical_specialty ,Mitral regurgitation ,Interventional cardiology ,medicine.drug_class ,business.industry ,MitraClip ,Pulmonary disease ,610 Medicine & health ,medicine.disease ,11171 Cardiocentro Ticino ,2705 Cardiology and Cardiovascular Medicine ,VALVULAR DISEASE ,Surgery ,Valvular Heart Disease ,INTERVENTIONAL CARDIOLOGY ,10209 Clinic for Cardiology ,medicine ,Natriuretic peptide ,Cardiology and Cardiovascular Medicine ,business ,Percutaneous Mitral Valve Repair ,Kidney disease - Abstract
Objective Analyse 2-year outcomes after MitraClip therapy and identify predictors of outcome. Methods Consecutive patients (n=74) undergoing MitraClip therapy were included in the MitraSWISS registry and followed prospectively. Results A reduction of mitral regurgitation (MR) to ≤ mild was achieved in 32 (43%) patients and to moderate in 31 (42%) patients; 16/63 (25%) patients with initially successful treatment developed recurrent moderate to severe or severe MR during the first year and only 1 patient did so during the second year. At 2 years, moderate or less MR was more frequently present in patients with a transmitral mean gradient
- Published
- 2014
- Full Text
- View/download PDF